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Lmortality at 30 days, with one death in a patient with functional MR after 5.8 years and
a degenerative MR patient after 3.2 years. There were no strokes with an average
follow-up of 2.41.8 years. There were sustained improvements in New York Heart
Association class (from 2.8  0.6 to 1.6  0.5, p <0.001) and MR grade (from 3.5 
0.9 to 0.4  0.5, p <0.001) at follow-up.
Conclusions: In this large single center experience, no patient required urgent cardiac
surgery for failed MitraClip procedure. Mitral valve repair rate in patients with
degenerative MR was high, and surgical options were preserved in the remaining
patients. Overall, cardiac surgical outcomes were excellent.
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Background: In primary or degenerative mitral regurgitation (DMR), the mitral valve
(MV) leaﬂets are structurally abnormal. The MitraClip device is the only percutaneous
leaﬂet-based therapy evaluated by both randomized and registry-based studies
utilizing core lab evaluation of patients with moderate to severe or severe ( 3+)
DMR. Functional MR has been separately and previously evaluated.
Methods: One-year data from the EVEREST II studies were analyzed for 509 patients
with severe baseline DMR, including 447 treated with MitraClip and 62 who
underwent a ﬁrst MV surgery.
Results: MV leaﬂet pathologies of prolapse and ﬂail were well-represented.
Compared to surgical candidates, high-risk DMR patients had STS mortality risk
scores of 12%, or surgeon assessment of excessive risk based on pre-speciﬁed
factors. They were older, more frequently had serious baseline co-morbidities, and
had more severe functional impairment than DMR patients in the RCT (Table 1).
Implant rates were consistently high across MitraClip DMR cohorts. Safety
outcomes reﬂected patient risk status. Lower-risk DMR patients who underwent
MV surgery had more complete MR reduction and greater improvement in LV
volumes than did lower-risk DMR patients who received MitraClip. Despite their
burden of co-morbidities, a large proportion of high-risk DMR patients who
received MitraClip achieved and maintained MR reduction to 2+ or less and did
not undergo MV surgery.Table 1. Baseline characteristics and outcomes* in EVEREST II High Risk (a)
and Low/Moderate Risk (b-d) DMR Cohorts
Baseline / Outcomes
(a). High Risk
MitraClip
(n=130)
(b). Continued
Access MitraClip
(n=187)
(c). RCT
MitraClip
(n=130)
(d). RCT
Surgery
(n=62)
Age 82  9 yrs 75  12 yrs 67  13 yrs 63  13 yrs
Coronary Artery Disease 74% 40% 37% 32%
Previous cardiovascular
surgery
52% 13% 12% 10%
Atrial Fibrillation 72% 53% 30% 29%
STS mortality risk score 13.6  8.4% n/a 3.7 3.1% 3.1  2.9%
LV Ejection Fraction 60  10% 60  7% 64  6% 65  6%
Anterior/Bileaﬂet Flail/
Prolapse
47% 39% 45% 35%
Posterior Flail/Prolapse 42% 50% 52% 61%
Mortality at 30 days 7.0% 1.1% 1.5% 3.2%
Major Adverse Events at 30
days
17.2% 10.2% 13.8% 51.6%
Freedom from MR >2+ at
1 year in surviving patients
86% 79% 84% 100%
Improvement in LVEDV at 1
year
-20  23 ml -13  22 ml -28  29 ml -48  36 ml
NYHA Class III/IV: Baseline
/ 1 year
79%/ 13% 52%/ 7% 41%/ 2% 39%/ 4%
Improvement in SF-36 PCS
at 1 year
5.9  8.9 6.2  8.9 5.2  9.8 4.2  10.6
*Echo data pending ﬁnal core lab review; MAE data pending ﬁnal CEC adjudication
JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: In the EVEREST II DMR experience, the safety proﬁle of the MitraClip
has been demonstrated in both high risk and lower risk cohorts. While surgery was
more effective in lower risk DMR patients, MitraClip provides meaningful
improvements of LV volumes, NYHA Class and Quality of Life in all DMR patient
cohorts, demonstrating that the MitraClip is an important therapeutic option for select
DMR patients.
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Background: Following CE approval in 2008, percutaneous mitral valve repair with
the MitraClip system (Abbott) has entered clinical practice in Europe, where it is
predominantly used to treat patients (pts) at high surgical risk. We sought to assess,
and elucidate the interrelation of, baseline echocardiographic variables predictive of
acute procedural failure in such pts.
Methods: The ﬁrst 300 consecutive pts (75  9 years, 190 men [63%]) who
underwent MitraClip therapy for grade 3+/4+ mitral regurgitation (MR) at our insti-
tution comprised the study cohort. All pts were adjudicated by heart team consensus as
not amenable to surgery. Procedural failure, deﬁned as discharge MR 3+, was
encountered in 32 patients (10.7%), with 11 aborted procedures (no clip implanted)
and 21 clip failures (MR 3+ despite clip implantation).
Results: Exact logistic regression analysis identiﬁed effective regurgitant oriﬁce area
(EROA), mitral valve oriﬁce area (MVOA), mean transmitral pressure gradient (TPG),
and MR severity (not quantiﬁed via EROA) as predictive of failure. Classiﬁcation tree
analysis (Figure) revealed EROA as the variable with highest discriminatory power,
followed by MVOA, TPG and MR severity. The highest incidence of clip failures
occurred in pts with EROA >0.71cm2, highest incidence of aborted procedures in pts
with MVOA 3.0cm2 and TPG 4mmHg.SConclusions: Baseline echocardiographic variables differentially impact the proce-
dural outcome of MitraClip therapy. Classiﬁcation tree analysis clariﬁes their inter-
relationship and may help to reduce the procedural failure rate.
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Background: Impaired renal function (RF) is strongly associated with poor outcome
in patients (pts) with chronic heart failure (HF). We sought to assess the acute effect of
MitraClip therapy (MC) on RF and its impact on mortality and HF rehospitalization.
Methods: In a retrospective analysis of 306 surgical high-risk pts (74.4  8.7 years,
197 men [64.4%]) with grade 3+ mitral regurgitation (MR) treated by MC, we
calculated glomerular ﬁltration rate (GFR) at baseline (BL) and discharge from
creatinine levels (CKD-EPI formula). GFR was converted into the 5 Kidney Disease
Outcomes Quality Initiative (KDOQI) stages. Pts were followed for 16  11 (range,
0.3-41) months.
Results: MC acutely improved RF (DKDOQI <0) in 82 pts (27%) and worsened RF
(DKDOQI >0) in 31 pts (10%), with no change in 63% of pts. Overall, survival wasacts/ORAL/Percutaneous Treatment of Mitral Valve Disease B29
